AU730326C - Humanized immunoglobulin reactive with alpha4beta7 integrin - Google Patents

Humanized immunoglobulin reactive with alpha4beta7 integrin

Info

Publication number
AU730326C
AU730326C AU39728/97A AU3972897A AU730326C AU 730326 C AU730326 C AU 730326C AU 39728/97 A AU39728/97 A AU 39728/97A AU 3972897 A AU3972897 A AU 3972897A AU 730326 C AU730326 C AU 730326C
Authority
AU
Australia
Prior art keywords
human
humanized immunoglobulin
antibody
act
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired, expires
Application number
AU39728/97A
Other languages
English (en)
Other versions
AU3972897A (en
AU730326B2 (en
Inventor
Mary M Bendig
S. Tarran Jones
Walter Newman
Paul D. Ponath
Douglas J Ringler
Jose Saldanha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24814673&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU730326(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of AU3972897A publication Critical patent/AU3972897A/en
Assigned to MILLENNIUM PHARMACEUTICALS, INC. reassignment MILLENNIUM PHARMACEUTICALS, INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: LEUKOSITE INCORPORATED
Priority to AU72596/00A priority Critical patent/AU778980B2/en
Application granted granted Critical
Publication of AU730326B2 publication Critical patent/AU730326B2/en
Priority to AU2005201265A priority patent/AU2005201265B2/en
Publication of AU730326C publication Critical patent/AU730326C/en
Priority to AU2008203508A priority patent/AU2008203508A1/en
Adjusted expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU39728/97A 1996-08-15 1997-08-06 Humanized immunoglobulin reactive with alpha4beta7 integrin Expired AU730326C (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU72596/00A AU778980B2 (en) 1996-08-15 2000-12-29 Humanized immunoglobulin reactive with alpha4beta7 integrin
AU2005201265A AU2005201265B2 (en) 1996-08-15 2005-03-23 Humanized immunoglobulin reactive with alpha4beta7 integrin
AU2008203508A AU2008203508A1 (en) 1996-08-15 2008-08-05 Humanized immunoglobulin reactive with a4B7 integrin

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/700,737 US7147851B1 (en) 1996-08-15 1996-08-15 Humanized immunoglobulin reactive with α4β7 integrin
US08/700737 1996-08-15
PCT/US1997/013884 WO1998006248A2 (en) 1996-08-15 1997-08-06 HUMANIZED IMMUNOGLOBULIN REACTIVE WITH α4β7 INTEGRIN

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU72596/00A Division AU778980B2 (en) 1996-08-15 2000-12-29 Humanized immunoglobulin reactive with alpha4beta7 integrin

Publications (3)

Publication Number Publication Date
AU3972897A AU3972897A (en) 1998-03-06
AU730326B2 AU730326B2 (en) 2001-03-01
AU730326C true AU730326C (en) 2005-06-16

Family

ID=24814673

Family Applications (1)

Application Number Title Priority Date Filing Date
AU39728/97A Expired AU730326C (en) 1996-08-15 1997-08-06 Humanized immunoglobulin reactive with alpha4beta7 integrin

Country Status (19)

Country Link
US (3) US7147851B1 (enExample)
EP (2) EP1710314A1 (enExample)
JP (3) JP4171071B2 (enExample)
CN (1) CN100406562C (enExample)
AT (1) ATE321788T1 (enExample)
AU (1) AU730326C (enExample)
BE (1) BE2014C068I2 (enExample)
BR (1) BRPI9711079B1 (enExample)
CA (1) CA2263106C (enExample)
DE (1) DE69735596T3 (enExample)
DK (1) DK0918797T4 (enExample)
ES (1) ES2262186T5 (enExample)
IL (3) IL128052A0 (enExample)
LT (1) LTC0918797I2 (enExample)
LU (1) LU92596I2 (enExample)
NZ (1) NZ334226A (enExample)
PT (1) PT918797E (enExample)
SI (1) SI0918797T2 (enExample)
WO (1) WO1998006248A2 (enExample)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7090845B2 (en) * 1998-05-13 2006-08-15 Genentech, Inc. Diagnosis and treatment of hepatic disorders
AU2011226857B2 (en) * 1998-05-13 2013-09-19 Genentech, Inc. Diagnosis and treatment of hepatic disorders
ATE316798T1 (de) * 1998-11-25 2006-02-15 Us Gov Health & Human Serv Antagoniste des alpha-e-beta-7 integrins als therapeutische agenzien gegen entzündungskrankheiten
KR100746522B1 (ko) * 1999-04-22 2007-08-07 바이오겐 아이덱 엠에이 인코포레이티드 인테그린 알파-4 서브유닛의 길항 물질을 사용하는섬유증의 치료 방법
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
AU2006220426B2 (en) * 2000-04-14 2008-10-30 Genentech Inc. Method of administering an antibody
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US20060246066A1 (en) * 2001-12-17 2006-11-02 Morgan Bryan P Cleavable reagents for specific delivery to disease sites
WO2003066662A2 (en) 2002-02-05 2003-08-14 Genentech, Inc. Protein purification
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
AU2003265235A1 (en) 2002-04-26 2003-12-19 Genetech, Inc. Non-affinity purification of proteins
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
HUE057124T2 (hu) 2002-05-02 2022-04-28 Wyeth Holdings Llc Calicheamicin származék - hordozó konjugátumok
WO2004063351A2 (en) * 2003-01-09 2004-07-29 Macrogenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
PL378571A1 (pl) * 2003-02-01 2006-05-02 Neuralab Limited Czynna immunizacja dla wytworzenia przeciwciał przeciw rozpuszczalnemu A-ß
DK3095793T3 (da) 2003-07-28 2020-05-25 Genentech Inc Reducering af udvaskning af protein A under en protein A-affinitetskromatografi
PL2520654T3 (pl) 2003-08-26 2017-08-31 The Regents Of The University Of Colorado, A Body Corporate Inhibitory aktywności proteazy serynowej i ich zastosowanie w sposobach i kompozycjach do leczenia zakażeń bakteryjnych
EP2135619A1 (en) 2003-12-10 2009-12-23 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
PE20051053A1 (es) 2004-01-09 2005-12-12 Pfizer ANTICUERPOS CONTRA MAdCAM
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
EP2322556B1 (en) 2004-09-03 2015-10-21 Genentech, Inc. Humanized anti-beta7 antagonists and uses therefor
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
TW200635607A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized Aβ antibodies for use in improving cognition
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
WO2007007151A2 (en) * 2005-07-11 2007-01-18 Pfizer Limited Use of anti-mad-cam antibody for the treatment of emphysema
WO2007007160A2 (en) * 2005-07-11 2007-01-18 Pfizer Limited Anti-madcam antibodies to treat fever
JP2009515552A (ja) * 2005-11-17 2009-04-16 ミレニアム・ファーマシューティカルズ・インコーポレイテッド α４β７インテグリン反応性ヒト化免疫グロブリン
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
WO2008079302A2 (en) 2006-12-21 2008-07-03 Millipore Corporation Purification of proteins
AU2008209404B2 (en) 2007-01-22 2012-08-16 Genentech, Inc. Polyelectrolyte precipitation and purification of antibodies
ES2707551T3 (es) * 2007-03-02 2019-04-04 Amgen Inc Métodos y composiciones para tratar enfermedades tumorales
JP2010521966A (ja) * 2007-03-20 2010-07-01 ミレニアム・ファーマシューティカルズ・インコーポレイテッド α４β７インテグリンに結合するヒト化免疫グロブリンをコードする核酸
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
CA2689941C (en) 2007-06-25 2019-10-29 Esbatech Ag Methods of modifying antibodies, and modified antibodies with improved functional properties
PL2188302T3 (pl) 2007-07-09 2018-04-30 Genentech, Inc. Zapobieganie redukcji wiązań disiarczkowych podczas rekombinacyjnego wytwarzania polipeptydów
DK2182983T3 (da) * 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
BRPI0817182A2 (pt) 2007-10-30 2015-03-17 Genentech Inc Método para purificar um anticorpo e composições
DK2243829T3 (da) * 2008-01-11 2014-11-17 Astellas Pharma Inc Forbedret humaniseret anti-humant alfa-9-integrin-antistof
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
WO2009151514A1 (en) 2008-06-11 2009-12-17 Millipore Corporation Stirred tank bioreactor
US10927144B2 (en) 2008-08-14 2021-02-23 Genentech, Inc. Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography
KR20110076918A (ko) 2008-09-10 2011-07-06 제넨테크, 인크. 단백질의 산화성 분해를 방지하기 위한 조성물 및 방법
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US20110020327A1 (en) 2008-12-16 2011-01-27 Millipore Corporation Purification of proteins
US20100190963A1 (en) 2008-12-16 2010-07-29 Millipore Corporation Stirred Tank Reactor And Method
WO2010099273A1 (en) 2009-02-27 2010-09-02 Genentech, Inc. Methods and compositions for protein labelling
KR101346530B1 (ko) * 2009-03-20 2013-12-31 암젠 인크 알파-4-베타-7 이종이량체 특이적 길항제 항체
AU2013205341B2 (en) * 2009-03-20 2016-05-05 Amgen Inc. Alpha-4-beta-7 heterodimer specific antagonist antibody
AU2016208453B2 (en) * 2009-03-20 2018-02-22 Amgen Inc. Alpha-4-beta-7 heterodimer specific antagonist antibody
EP2429582A4 (en) 2009-05-13 2013-01-23 Genzyme Corp IMMUNOGLOBULINS ANTI-CD52 HUMAN
ES2793348T5 (en) 2009-08-11 2025-04-11 Hoffmann La Roche Production of proteins in glutamine-free cell culture media
PL2473617T3 (pl) 2009-09-01 2020-06-29 F. Hoffmann-La Roche Ag Ulepszone oczyszczanie białka poprzez zmodyfikowaną elucję z białka A
HRP20240920T1 (hr) 2009-10-26 2024-10-11 F. Hoffmann - La Roche Ag Postupak za proizvodnju glikoziliranog imunoglobulina
MX354867B (es) 2010-03-22 2018-03-23 Genentech Inc Star Composiciones y métodos útiles para estabilizar formulaciones que contienen proteína.
KR20130060227A (ko) 2010-05-03 2013-06-07 제넨테크, 인크. 단백질-함유 제제의 점도 감소에 유용한 조성물 및 방법
EP2571903B1 (en) 2010-05-17 2019-09-04 EMD Millipore Corporation Stimulus responsive polymers for the purification of biomolecules
KR101869987B1 (ko) 2010-05-28 2018-07-20 제넨테크, 인크. 락테이트 데히드로게나제 및 피루베이트 데히드로게나제 키나제의 발현의 하향조절에 의한 락테이트 수준의 감소 및 폴리펩티드 생산의 증가
CA2802756C (en) 2010-06-24 2021-05-04 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
RU2013110844A (ru) 2010-08-13 2014-09-20 Дженентек, Инк. АНТИТЕЛА ПРОТИВ IL-1β И IL-18, ИСПОЛЬЗУЕМЫЕ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
US10040855B2 (en) 2011-05-02 2018-08-07 Millennium Pharmaceuticals, Inc. Formulation for anti-α4β7 antibody
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
US9938353B2 (en) 2011-06-24 2018-04-10 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
PL2794635T3 (pl) 2011-12-22 2019-02-28 F.Hoffmann-La Roche Ag Membranowa chromatografia jonowymienna
US10745468B2 (en) 2011-12-22 2020-08-18 Kota Biotherapeutics, Llc Compositions and methods for modified B cells expressing reassigned biological agents
CA2896951A1 (en) * 2012-01-10 2013-07-18 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
EA034583B1 (ru) * 2012-01-12 2020-02-21 Милленниум Фармасьютикалз, Инк. ПРИМЕНЕНИЯ АНТИ-α4β7 АНТИТЕЛА
AU2013240280A1 (en) 2012-03-27 2014-10-16 Genentech, Inc. Improved harvest operations for recombinant proteins
CN103374073A (zh) * 2012-04-26 2013-10-30 中国科学院上海生命科学研究院 识别活化形式整合素α4β7的人源化单克隆抗体
NZ701915A (en) 2012-05-18 2016-11-25 Genentech Inc High-concentration monoclonal antibody formulations
WO2014100095A1 (en) 2012-12-19 2014-06-26 Genentech, Inc. Methods and compositions for radiohalogen protein labeling
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
SG11201700097WA (en) 2014-07-09 2017-02-27 Genentech Inc Ph adjustment to improve thaw recovery of cell banks
WO2016057424A1 (en) 2014-10-06 2016-04-14 Chemocentryx, Inc. Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies
EP3581585A1 (en) 2014-11-26 2019-12-18 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
US20170360926A1 (en) 2014-12-24 2017-12-21 Millennium Pharmaceuticals, Inc. PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-alpha4beta7 INTEGRIN ANTIBODY
MA41636A (fr) 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
US10654931B2 (en) * 2015-08-11 2020-05-19 Osaka University Antibody
CN108348581B (zh) 2015-09-04 2022-07-01 斯克利普斯研究所 胰岛素免疫球蛋白融合蛋白
EP3397274A1 (en) 2015-12-31 2018-11-07 The Regents of the University of Colorado, a body corporate Methods and uses for alpha-1 antitrypsin or recombinant forms thereof, on steroid-refractory graft versus host disease involving gastrointestinal complications
CN109153721A (zh) * 2016-03-14 2019-01-04 千禧制药公司 治疗或预防移植物抗宿主疾病的方法
BR112018068628A2 (pt) * 2016-03-14 2019-07-30 Millennium Pharm Inc método de prevenção de doença do enxerto contra hospedeiro
US11760803B2 (en) 2016-03-24 2023-09-19 Takeda Pharmaceutical Company Limited Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
TW201735949A (zh) 2016-03-24 2017-10-16 千禧製藥公司 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
EP3436610A1 (en) 2016-03-29 2019-02-06 Geltor, Inc. Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1
JP7162533B2 (ja) 2016-05-04 2022-10-28 ミレニアム ファーマシューティカルズ， インコーポレイテッド 炎症性腸疾患の治療を目的とする三剤併用療法
CN109563482A (zh) * 2016-06-10 2019-04-02 埃尔瓦有限公司 含表达异于分泌免疫球蛋白和细胞溶解功能的膜免疫球蛋白的b淋巴细胞系的组合物和方法
WO2017218434A1 (en) 2016-06-12 2017-12-21 Millennium Pharmaceuticals, Inc. Method of treating inflammatory bowel disease
WO2018104893A1 (en) 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life
CA3044686A1 (en) 2016-12-22 2018-06-28 Genentech, Inc. Methods and formulations for reducing reconstitution time of lyophilized polypeptides
US20200179486A1 (en) 2017-04-28 2020-06-11 Millennium Pharmaceuticals, Inc. Method of treating pediatric disorders
CR20200076A (es) 2017-07-14 2020-06-10 Pfizer ANTICUERPOS CONTRA MAdCAM
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
HRP20240584T1 (hr) 2018-07-03 2024-07-19 Bristol-Myers Squibb Company Postupak proizvodnje rekombinantnih proteina
KR20210074341A (ko) 2018-10-10 2021-06-21 베링거 인겔하임 인터내셔날 게엠베하 고밀도 생물 반응기 배양에서 막 기체 전달을 위한 방법
JP2022510218A (ja) * 2018-11-30 2022-01-26 メモリアル スローン ケタリング キャンサー センター ヘテロ二量体四価特異性抗体およびこれらの使用
CN113660953A (zh) 2019-04-01 2021-11-16 豪夫迈·罗氏有限公司 用于稳定含蛋白质制剂的组合物和方法
KR20210151930A (ko) 2019-04-12 2021-12-14 젤터, 인코포레이티드 재조합 엘라스틴 및 이의 제조
WO2020215019A1 (en) * 2019-04-17 2020-10-22 Millennium Pharmaceuticals, Inc. Alpha4beta7 inhibitor and il-23 inhibitor combination therapy
MA56130A (fr) * 2019-06-10 2022-04-13 Takeda Pharmaceuticals Co Procédés de culture cellulaire et compositions pour la production d'anticorps
CN118909119A (zh) * 2019-06-10 2024-11-08 武田药品工业株式会社 抗体纯化方法及其组合物
KR20220039777A (ko) 2019-08-01 2022-03-29 브리스톨-마이어스 스큅 컴퍼니 유가식 세포 배양에서 단백질 생산성을 개선시키는 방법
US12486525B2 (en) 2020-09-22 2025-12-02 Bristol-Myers Squibb Company Methods for increasing productivity of therapeutic proteins
US20250115666A1 (en) 2021-08-05 2025-04-10 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
WO2023049687A1 (en) 2021-09-21 2023-03-30 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container
TW202413442A (zh) 2022-06-16 2024-04-01 美商希佛隆有限責任公司 抗pd-1抗體減弱之il-2免疫結合物及其用途
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
WO2024252368A2 (en) 2023-06-09 2024-12-12 Takeda Pharmaceutical Company Limited Methods and compositions for treating ulcerative colitis
US20250195677A1 (en) 2023-12-19 2025-06-19 Cephalon Llc Uses for attenuated il-2 immunoconjugates
CN117777292B (zh) * 2023-12-28 2024-10-18 天津大学 抗整合素α4β7纳米抗体及其用途
WO2025149974A1 (en) 2024-01-11 2025-07-17 Takeda Pharmaceutical Company Limited Combination therapy with an anti-alpha4beta7 antibody
WO2025177214A1 (en) 2024-02-20 2025-08-28 Takeda Pharmaceutical Company Limited Therapeutic methods

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06303990A (ja) * 1993-04-24 1994-11-01 Kanebo Ltd モノクローナル抗体、それを産生するハイブリドーマおよび該抗体の製造方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3220049A1 (de) 1982-05-27 1983-12-01 Universal Maschinenfabrik Dr. Rudolf Schieber GmbH & Co KG, 7081 Westhausen Strick- und umhaengeschlosskombination fuer v-bett-flachstrickmaschinen mit schiebernadeln
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4699880A (en) * 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5538724A (en) 1987-08-11 1996-07-23 The Board Of Trustees For The Leland Stanford Junior Univ. Method of control leukocyte extravasation
US5403919A (en) 1987-08-11 1995-04-04 Board Of Trustees Of The Leland Stanford Junior University Stanford University Method to control leukocyte extravasation
DE3852236T2 (de) 1987-08-11 1995-04-06 Univ Leland Stanford Junior Verfahren zur Kontrolle der Leukozyten-Extravasation.
US5223392A (en) * 1988-01-25 1993-06-29 Exocell, Inc. Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
JPH04504501A (ja) 1988-12-23 1992-08-13 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ ホーミング配列およびそれらの使用
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
IL95501A (en) 1989-09-01 1997-04-15 Hutchinson Fred Cancer Res Inhibition by antibodies of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction, and pharmaceutical compositions containing said antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ATE247168T1 (de) 1991-03-06 2003-08-15 Merck Patent Gmbh Humanisierte monoklonale antikörper
US5665595A (en) * 1991-06-07 1997-09-09 Dowelanco Immunoglobulins against insect tissue
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
US5871734A (en) 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
ES2103468T3 (es) 1992-02-12 1997-09-16 Biogen Inc Tratamiento de la inflamacion intestinal.
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
WO1994012214A1 (en) 1992-12-01 1994-06-09 Protein Design Labs, Inc. Humanized antibodies reactive with cd18
WO1994013312A1 (en) 1992-12-15 1994-06-23 The Board Of Trustees Of The Leland Stanford Junior University Mucosal vascular addressin, dna and expression
CA2153692C (en) 1993-01-12 2011-11-08 Roy R. Lobb Recombinant anti-vla4 antibody molecules
DK0682529T4 (da) 1993-02-09 2006-05-15 Biogen Idec Inc Antistof til behandling af insulinkrævende diabetes
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
CA2182013C (en) 1994-01-25 2007-07-17 Mary M. Bendig Humanized antibodies against leukocyte adhesion molecule vla-4
US6551593B1 (en) * 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US6037324A (en) * 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06303990A (ja) * 1993-04-24 1994-11-01 Kanebo Ltd モノクローナル抗体、それを産生するハイブリドーマおよび該抗体の製造方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANDREW ET AL. J.IMMUNOL. 1994. 153(9):3847-61 *

Also Published As

Publication number Publication date
CA2263106A1 (en) 1998-02-19
US20090011464A1 (en) 2009-01-08
NZ334226A (en) 2000-10-27
SI0918797T2 (sl) 2016-01-29
CA2263106C (en) 2010-08-03
ATE321788T1 (de) 2006-04-15
AU3972897A (en) 1998-03-06
JP4578536B2 (ja) 2010-11-10
JP2008281562A (ja) 2008-11-20
DK0918797T3 (da) 2006-07-31
JP5166483B2 (ja) 2013-03-21
EP1710314A1 (en) 2006-10-11
EP0918797B2 (en) 2015-09-23
DE69735596T2 (de) 2006-12-21
IL128052A0 (en) 1999-11-30
LTC0918797I2 (lt) 2017-05-10
BRPI9711079B8 (enExample) 2021-05-25
US7147851B1 (en) 2006-12-12
WO1998006248A2 (en) 1998-02-19
PT918797E (pt) 2006-08-31
EP0918797A2 (en) 1999-06-02
IL128052A (en) 2006-08-20
BE2014C068I2 (enExample) 2017-09-22
SI0918797T1 (sl) 2006-10-31
CN100406562C (zh) 2008-07-30
ES2262186T5 (es) 2015-12-11
JP2001507210A (ja) 2001-06-05
US7402410B2 (en) 2008-07-22
DE69735596T3 (de) 2016-02-25
HK1021822A1 (en) 2000-07-07
WO1998006248A3 (en) 1998-05-07
ES2262186T3 (es) 2006-11-16
BR9711079A (pt) 2000-06-06
US20060292140A1 (en) 2006-12-28
BRPI9711079B1 (pt) 2017-06-20
LU92596I2 (fr) 2015-01-12
EP0918797B1 (en) 2006-03-29
JP2010246548A (ja) 2010-11-04
IL175570A0 (en) 2006-09-05
AU730326B2 (en) 2001-03-01
CN1227607A (zh) 1999-09-01
DE69735596D1 (de) 2006-05-18
DK0918797T4 (en) 2016-01-11
JP4171071B2 (ja) 2008-10-22

Similar Documents

Publication Publication Date Title
AU730326C (en) Humanized immunoglobulin reactive with alpha4beta7 integrin
CA2153692C (en) Recombinant anti-vla4 antibody molecules
AU651623B2 (en) Antibodies directed against CD3
JP4065554B2 (ja) 抗体の調製
HUP0102005A2 (hu) CD23 elleni antitestek, ezek származékai, és gyógyászati alkalmazásuk
AU2005201265B2 (en) Humanized immunoglobulin reactive with alpha4beta7 integrin
AU778980B2 (en) Humanized immunoglobulin reactive with alpha4beta7 integrin
AU2008203508A1 (en) Humanized immunoglobulin reactive with a4B7 integrin
HK1097874A (en) Humanized immunoglobulin reactive with alpha4beta7 integrin
HK1021822B (en) Humanized immunoglobulin reactive with alpha4beta7 integrin
HK1021822C (en) Humanized immunoglobulin reactive with alpha4beta7 integrin
MXPA99001462A (es) Inmunoglobulina humanizada reactiva con (alfa4beta7) integrina
HK1011031B (en) Recombinant anti-vla4 antibody molecules

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ON=MILLENIUM PHARMACEUTICALS, INC.; FT=THE FORMER

SREP Specification republished
TH Corrigenda

Free format text: IN VOL 15, NO 5, PAGE(S) 917 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX IN THE NAME OF LEUKOSITE, INC. SERIAL NO. 730326, INID (71), AMEND THE APPLICANT TO READ MILLENNIUM PHARMACEUTICALS, INC.

FGA Letters patent sealed or granted (standard patent)